BioXcel Therapeutics Inc
(STU:BX2)
€
0.4469
-0.0927 (-17.18%)
Market Cap: 18.50 Mil
Enterprise Value: 84.72 Mil
PE Ratio: 0
PB Ratio: 0
GF Score: 16/100 BioXcel Therapeutics Inc at Bank of America Merrill Lynch Napa Healthcare Conference (Virtual) Transcript
Jun 24, 2020 / 02:30PM GMT
Release Date Price:
€52
(+2.97%)
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Okay. Welcome to the third day of the BofA Virtual Napa Conference. We all would rather be in actual Napa, but that's okay. Maybe that's aspirational for next year.
I'm Geoff Meacham. I'm the Senior Biopharma Analyst here at BofA. And I have Scott Puckhaber on my team who's on the line as well. The first morning session that we have today is for BioXcel Therapeutics. And we're really excited to have 2 folks: Vimal Mehta, who's the CEO and Founder; and then Will Kane, who is 1 week into the seat as Chief Commercial Officer.
Guys, are you there?
Vimal D. Mehta
BioXcel Therapeutics, Inc. - Founder, CEO, President, Secretary & Director
Yes, we are here.
Geoffrey Christopher Meacham
BofA Merrill Lynch, Research Division - Research Analyst
Okay. Perfect.
William P. Kane
BioXcel Therapeutics, Inc. - Executive VP & Chief Commercial Officer
Yes. All set.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot